TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31958790

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30759778

Group type: EXPERIMENTAL
Intervention: Chen-Style Tai Chi (TC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Core Stabilization training (CST)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (maintained unaltered lifestyle)
Number of subjects: 43
Study: 28333860

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 353

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 353
Study: 26915276

Group type: EXPERIMENTAL
Intervention: Reduction group
Number of subjects: 45

Group type: COMPARATOR
Intervention: In situ fusion group
Number of subjects: 45
Study: 25085447

Group type: EXPERIMENTAL
Intervention: Culturally sensitive wellbeing intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 22664795

Group type: EXPERIMENTAL
Intervention: Participation in the IHDP intervention
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Caregiver's report on the youth's school progress
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Youth report of behavioral problems
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Youth's expectations of future success
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Youth's relationship with their parents
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Observed IQ
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Expectations of the youth's educational attainment
Number of subjects: 229
Study: 19348544

Group type: EXPERIMENTAL
Intervention: Simulated distributions of pronunciation times using combinations of lognormal and power-law behavior.
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Hazard function simulations.
Number of subjects: 1100
Study: 17585028

Group type: COMPARATOR
Intervention: Control diet (93 microg phylloquinone/d) for 5 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phylloquinone-restricted diet (11 microg/d) for 15 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repletion diet with phylloquinone (206 microg/d) for 10 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repletion diet with dihydrophylloquinone (240 microg/d) for 10 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repletion diet with either phylloquinone or dihydrophylloquinone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Total urinary excretion
Number of subjects: 9
Study: 15378434

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 12214463

Group type: EXPERIMENTAL
Intervention: TAP therapy (TXL 160 mg/m2 3 h, day 2, ADM 45 mg/m2, day 1, CDDP 50 mg/m2 day 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AP therapy (ADM 60 mg/m2, CDDP 50 mg/m2)
Number of subjects: 0
Study: 12078199

Group type: EXPERIMENTAL
Intervention: 3 tablets of albendazole composite
Number of subjects: 5590

Group type: EXPERIMENTAL
Intervention: 2 tablets of albendazole composite
Number of subjects: 5590

Group type: COMPARATOR
Intervention: Single dose of 400 mg of albendazole
Number of subjects: 5590

Group type: COMPARATOR
Intervention: Single dose of 10 mg base/kg of pyrantel pamoate
Number of subjects: 5590

Group type: EXPERIMENTAL
Intervention: 1.5 tablets of albendazole composite
Number of subjects: 5590

Group type: COMPARATOR
Intervention: Single dose of pyrantel pamoate
Number of subjects: 5590
Study: 7804990

Group type: EXPERIMENTAL
Intervention: Sunny Days, Healthy Ways curriculum (elementary school)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Be Sun Safe curriculum (preschool)
Number of subjects: 0
Study: 2686955

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g) administered as i.v. bolus 30 min before operation
Number of subjects: 686

Group type: COMPARATOR
Intervention: Piperacillin (2 g) administered as i.v. bolus 30 min before operation
Number of subjects: 686
Study: 4597119

Group type: EXPERIMENTAL
Intervention: 0.5% salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5% rimiterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline
Number of subjects: 15
Study: 31466530

Group type: EXPERIMENTAL
Intervention: Extremely Randomized Tree (ERT) algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERT approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERT methodology
Number of subjects: 0
Study: 28363687

Group type: EXPERIMENTAL
Intervention: Aggressive treatment strategy with angiographic guidance (n=450)
Number of subjects: 899

Group type: COMPARATOR
Intervention: Conservative treatment strategy with angiographic guidance (n=449)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Aggressive treatment strategy
Number of subjects: 899

Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 899
Study: 26131189

Group type: EXPERIMENTAL
Intervention: LJCT (Lower Joint Cavity Treatment)
Number of subjects: 56

Group type: COMPARATOR
Intervention: UJCT (Upper Joint Cavity Treatment)
Number of subjects: 56
Study: 23434107

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous epidural analgesia (CEA)
Number of subjects: 66
Study: 22104275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: WHO definition of metabolic syndrome
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: ATPIII definition of metabolic syndrome
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: IDF definition of metabolic syndrome
Number of subjects: 4900
Study: 19834012

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) 40,000 IU intravenously
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 522
Study: 16467019

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg daily for at least 60 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (only emollients for topical therapy)
Number of subjects: 76
Study: 12789169

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study: 11288031

Group type: EXPERIMENTAL
Intervention: Insulin infusion (50 mU/kg/h) for 4 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 16
Study: 9107633

Group type: EXPERIMENTAL
Intervention: Double Product (DP) measured above the blood lactate threshold (LT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) measured above the blood lactate threshold (LT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) measured above the blood lactate threshold (LT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Constant work rate exercise sessions at various submaximal intensities
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DP break point (DPBP) determining protocol
Number of subjects: 90
Study: 8461565

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) administered continuously
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) administered cyclically
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) administered cyclically (50-60 mg/day)
Number of subjects: 50
Study: 3488178

Group type: EXPERIMENTAL
Intervention: Fibrin sealing during lymph node dissections (n = 26)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fibrin sealing for treatment of manifest lymph fistulae (n = 9)
Number of subjects: 35
Study: 29505477

Group type: EXPERIMENTAL
Intervention: Transparent cap-assisted endoscopic sclerotherapy
Number of subjects: 120
Study: 27524190

Group type: EXPERIMENTAL
Intervention: CEE+ MPA sequential therapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: E2V+ MPA sequential therapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: E2V+ P sequential therapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Kuntai capsule
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cohosh extract
Number of subjects: 140
Study: 24467258

Group type: EXPERIMENTAL
Intervention: Risk-accepting passenger
Number of subjects: 66

Group type: COMPARATOR
Intervention: Risk-averse passenger
Number of subjects: 66
Study: 22244909

Group type: EXPERIMENTAL
Intervention: Class I radical hysterectomy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Class III radical hysterectomy
Number of subjects: 125
Study: 20705220

Group type: EXPERIMENTAL
Intervention: Proposed changes in low-density lipoprotein cholesterol management guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current management guidelines for low-density lipoprotein cholesterol
Number of subjects: 0
Study: 18580019

Group type: EXPERIMENTAL
Intervention: Antibiotic-lock therapy using vancomycin and gentamycin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine TCC management
Number of subjects: 69
Study: 16197624

Group type: EXPERIMENTAL
Intervention: Irinotecan 200 mg/m2 on day 1, levo-leucovorin (LV) 250 mg/m2, and 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Irinotecan/5-FU/LV regimen
Number of subjects: 254
Study: 12017209

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 11757258

Group type: EXPERIMENTAL
Intervention: Cooperative-creative program of assertive behavior and self-concept, implemented through group play-sessions once a week during the academic year
Number of subjects: 154
Study: 8674567

Group type: EXPERIMENTAL
Intervention: Intracavitary silver nitrate (AgNO3) stick insertion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional excision technique
Number of subjects: 50
Study: 2335304

Group type: EXPERIMENTAL
Intervention: Single-session educational intervention on DSM-IIIR affective and anxiety disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 879070

Group type: EXPERIMENTAL
Intervention: Formula containing cystine at 6 mg/100 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula containing cystine at 28 mg/100 ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intake of tyrosine less than 50 mg/kg of body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary approach to reduce elevated plasma tyrosine levels
Number of subjects: 0
Study: 31418805

Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate (BSS)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 27813208

Group type: EXPERIMENTAL
Intervention: Cognitive bias training programme
Number of subjects: 2
Study: 26011508

Group type: EXPERIMENTAL
Intervention: Personality-targeted intervention program (Adventure trial) delivered by trained teachers
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Sensation-seeking intervention
Number of subjects: 1038
Study: 23542637

Group type: EXPERIMENTAL
Intervention: valacyclovir 1000 mg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: acyclovir 400 mg twice daily
Number of subjects: 34
Study: 21884720

Group type: EXPERIMENTAL
Intervention: Carisoprodol 700 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carisoprodol 350 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (0 mg carisoprodol)
Number of subjects: 15
Study: 17944966

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polylactide-polyglycolide acid sponge (Fisiograft)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Natural healing by clot formation
Number of subjects: 20
Study: 16857993

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Surgical patients
Number of subjects: 290

Group type: COMPARATOR
Intervention: Medical patients
Number of subjects: 290
Study: 14659122

Group type: EXPERIMENTAL
Intervention: USC/Van Nuys Prognostic Index
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Mastectomy or breast conservation with or without radiation therapy
Number of subjects: 1036
Study: 10864708

Group type: EXPERIMENTAL
Intervention: Behavioural measures of pain assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-rating pain scores
Number of subjects: 0
Study: 9176844

Group type: EXPERIMENTAL
Intervention: High-sodium diet (200 mmol/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet (20 mmol/day)
Number of subjects: 12
Study: 1412641

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg body weight)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg body weight) + Desipramine (1.3-2.8 mg/kg body weight) daily for 3 days
Number of subjects: 53
Study: 3874641

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg kg‐1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Etomidate 0.2 mg kg‐1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Methohexitone 1.5 mg kg‐1
Number of subjects: 71
Study: 30338845

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 80 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 90 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 100 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 110 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 120 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 130 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 140 CPM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chest compression frequency of 150 CPM
Number of subjects: 40
Study: 28502186

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (VP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination therapy with VP, indomethacin, and treatment of bacterial vaginosis (BV)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Dydrogesterone, 17-OH progesterone (17OHP), and micronized oral progesterone (OP)
Number of subjects: 95
Study: 26242382

Group type: EXPERIMENTAL
Intervention: JNJ‐54452840 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: JNJ‐54452840 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: JNJ‐54452840 240 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 32
Study: 24518260

Group type: EXPERIMENTAL
Intervention: MEG-fMRI data correlation analysis during cognitive tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency correlation analysis
Number of subjects: 0
Study: 22686076

Group type: EXPERIMENTAL
Intervention: Xinganbao Capsule (8 capsules, three times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heluo Shugan Tablet (5 pills, thrice daily)
Number of subjects: 60
Study: 20105114

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 16580386

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily plus oral contraceptive pill (OCP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: OCP alone
Number of subjects: 48
Study: 14749148

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ramosetron 0.15 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg vs Ramosetron 0.6 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 10997687

Group type: EXPERIMENTAL
Intervention: Chronic hyperglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of glucose-induced pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased reactive oxygen species (ROS) production
Number of subjects: 0
Study: 9066400

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control
Number of subjects: 324
Study: 8299674

Group type: COMPARATOR
Intervention: Sauna (3 x 10 min; temperature 80-100 degrees C; relative humidity 30-50%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Post-sauna period
Number of subjects: 6
Study: 2945527

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 10
Study: 31143922

Group type: EXPERIMENTAL
Intervention: Cervical headgear worn for 12 hours daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cervical headgear worn during the day (8 am‐8 pm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cervical headgear worn during the night (8 pm‐8 am)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cervical headgear compliance during summer months
Number of subjects: 20
Study: 29540069

Group type: EXPERIMENTAL
Intervention: Carbon monoxide inhalation (carboxyhemoglobin 22%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26847398

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVI) irrigation
Number of subjects: 3027

Group type: COMPARATOR
Intervention: No Betadine irrigation (Control)
Number of subjects: 3027
Study: 25191663

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Midazolam and Propofol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pre-operational stress
Number of subjects: 33
Study: 23471324

Group type: EXPERIMENTAL
Intervention: Aspherical intraocular lens
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spherical intraocular lens
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Yellow tinted intraocular lens
Number of subjects: 52

Group type: COMPARATOR
Intervention: Acrylic ultraviolet filter IOL
Number of subjects: 52
Study: 22885319

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ondansetron (4mg)
Number of subjects: 130
Study: 18246730

Group type: EXPERIMENTAL
Intervention: PCR for detection of E.histolytica DNA in liver abscess aspirate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antigen detection by ELISA in liver abscess aspirate
Number of subjects: 30
Study: 16915076

Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 106
Study: 12675644

Group type: EXPERIMENTAL
Intervention: Intensified management with diet, exercise, and insulin
Number of subjects: 55
Study: 10872954

Group type: EXPERIMENTAL
Intervention: Continuous non-surgical therapy (one or more non-surgical procedures performed during 3 successive years)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Intermittent non-surgical therapy
Number of subjects: 1021
Study: 9171121

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) + laparoscopic cholecystectomy (LC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (ES) alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study: 7901256

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ibopamine
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: COMPARATOR
Intervention: Digoxin and Ibopamine
Number of subjects: 161
Study: 3004797

Group type: EXPERIMENTAL
Intervention: Isotope washout technique
Number of subjects: 48
Study: 30522484

Group type: EXPERIMENTAL
Intervention: Proactive patient follow-up intervention
Number of subjects: 1900
Study: 27689478

Group type: EXPERIMENTAL
Intervention: Youth All Engaged! (text message intervention)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Teen Outreach Program (control)
Number of subjects: 852
Study: 25014615

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 120
Study: 21420841

Group type: EXPERIMENTAL
Intervention: High fat diet (>40% calories from fat)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low fat diet (approximately 20% calories from fat)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low fat meal
Number of subjects: 29
Study: 19439362

Group type: EXPERIMENTAL
Intervention: General practitioner-based minimal intervention for workers with stress-related sick leave (MISS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 18703552

Group type: EXPERIMENTAL
Intervention: 23-gauge system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20-gauge system
Number of subjects: 60
Study: 15722300

Group type: EXPERIMENTAL
Intervention: CT-112 (0.25% eye drops, 4 times a day for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (4 times a day for 8 weeks)
Number of subjects: 34
Study: 12698515

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 112
Study: 10376453

Group type: EXPERIMENTAL
Intervention: Ligation plus sclerotherapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Ligation alone
Number of subjects: 103
Study: 8872083

Group type: EXPERIMENTAL
Intervention: Memory handbook (MHB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study: 1844692

Group type: EXPERIMENTAL
Intervention: Treatment effects across centers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper confidence limits for delta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests based on upper confidence limits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Example from a four‐center clinical trial
Number of subjects: 0
Study: 6336714

Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vegetable protein diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mixed protein diet
Number of subjects: 8